Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Total Current Liabilities (2021 - 2026)

Indivior Pharmaceuticals has reported Total Current Liabilities over the past 6 years, most recently at $779.0 million for Q1 2026.

  • For Q1 2026, Total Current Liabilities fell 22.49% year-over-year to $779.0 million; the TTM value through Mar 2026 reached $779.0 million, down 22.49%, while the annual FY2025 figure was $914.0 million, 1.08% down from the prior year.
  • Total Current Liabilities for Q1 2026 was $779.0 million at Indivior Pharmaceuticals, down from $914.0 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $1.3 billion in Q4 2023 and troughed at $779.0 million in Q1 2026.
  • A 5-year average of $992.9 million and a median of $985.0 million in 2025 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: increased 26.74% in 2022 and later fell 27.87% in 2024.
  • Year by year, Total Current Liabilities stood at $1.0 billion in 2022, then rose by 25.71% to $1.3 billion in 2023, then fell by 27.87% to $924.0 million in 2024, then dropped by 1.08% to $914.0 million in 2025, then decreased by 14.77% to $779.0 million in 2026.
  • Business Quant data shows Total Current Liabilities for INDV at $779.0 million in Q1 2026, $914.0 million in Q4 2025, and $965.0 million in Q3 2025.